Agile Therapeutics Inc (AGRX) Sees Significant Increase in Short Interest

Agile Therapeutics Inc (NASDAQ:AGRX) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 2,529,877 shares, a growth of 124.2% from the October 15th total of 1,128,282 shares. Currently, 10.6% of the company’s stock are sold short. Based on an average daily trading volume, of 4,351,706 shares, the short-interest ratio is presently 0.6 days.

NASDAQ AGRX opened at $1.00 on Friday. Agile Therapeutics has a 12-month low of $0.23 and a 12-month high of $5.33. The firm has a market capitalization of $33.08 million, a price-to-earnings ratio of -1.10 and a beta of -0.95.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. As a group, sell-side analysts anticipate that Agile Therapeutics will post -0.6 EPS for the current fiscal year.

AGRX has been the subject of a number of recent research reports. ValuEngine raised shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. HC Wainwright set a $4.00 price objective on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $4.00.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP lifted its stake in Agile Therapeutics by 62.8% during the first quarter. Dimensional Fund Advisors LP now owns 145,070 shares of the specialty pharmaceutical company’s stock worth $373,000 after purchasing an additional 55,937 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Agile Therapeutics by 76.3% during the second quarter. Renaissance Technologies LLC now owns 792,990 shares of the specialty pharmaceutical company’s stock worth $392,000 after purchasing an additional 343,290 shares during the last quarter. Finally, Fosun International Ltd bought a new stake in Agile Therapeutics during the third quarter worth about $180,000. 51.92% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Agile Therapeutics Inc (AGRX) Sees Significant Increase in Short Interest” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://sportsperspectives.com/2018/11/10/agile-therapeutics-inc-agrx-sees-significant-increase-in-short-interest.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Read More: Stock Symbols and CUSIP Explained

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply